Reply to potential issues with the use of teriparatide after denosumab-related osteonecrosis of the jaw

wbldb

Everts-Graber, Judith^1,2; Burkhard, John-Patrik^3,4; Schaller, Benoît³; Reichenbach, Stephan^2,5; Lehmann, Thomas¹

J Bone Miner Res. October 2022;37(10):2046-2047

Cited Works (4)

Year	Entry
2015	Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie S-AM. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. September 19-25, 2015;386(9999):1147.
2021	Everts-Graber J, Reichenbach S, Gahl B, Ziswiler H, Studer U, Lehmann T. Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study. Bone. March 2021;144:115830.
2022	Everts-Graber J, Lehmann D, Burkard J-P, Schaller B, Gahl B, Häuselmann H, Studer U, Ziswiler H-R, Reichenbach S, Lehmann T. Risk of osteonecrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis. J Bone Miner Res. February 2022;37(2):340-348.
2022	Park K-S, Jung SM, Park Y-J, Kim K-J. Denosumab-related osteonecrosis of the jaw may not be a subject of teriparatide treatment. J Bone Miner Res. October 2022;37(10):2044-2045.